Literature DB >> 17522786

Neurointensive care management of raised intracranial pressure caused by severe valproic acid intoxication.

Niklas Marklund1, Per Enblad, Elisabeth Ronne-Engström.   

Abstract

INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication. A previously healthy 25-year old male with mild tonic-clonic epilepsy was found unconscious with serum VPA levels >10,000 micromol/l. The patient deteriorated to Glasgow Motor Scale score (GMS) 2 and a CT scan showed signs of raised ICP. Early ICP was elevated, >50 mm Hg, and continuous EEG monitoring showed isoelectric readings.
METHODS: The patient was treated with an ICP-guided protocol including mild hyperventilation, normovolemia, head elevation and intermittent doses of mannitol. Due to refractory elevations of ICP, high-dose pentobarbital infusion was initiated, and ICP gradually normalised.
RESULTS: There were several systemic complications including coagulopathy, hypocalcemia and pancreatitis. The patient remained in a depressed level of consciousness for 2 months but gradually recovered, showing a good recovery with minor subjective cognitive deficits by 6 months.
CONCLUSION: We conclude that NIC may be an important treatment option in cases of severe intoxication causing cerebral swelling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522786     DOI: 10.1007/s12028-007-0060-6

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  25 in total

1.  Massive cerebral edema after I.V. cyclosporin overdose.

Authors:  M de Perrot; A Spiliopoulos; S Cottini; L Nicod; B Ricou
Journal:  Transplantation       Date:  2000-10-27       Impact factor: 4.939

2.  Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure.

Authors:  W J Triggs; R L Gilmore; D S Millington; J Cibula; T S Bunch; E Harman
Journal:  Int J Clin Pharmacol Ther       Date:  1997-09       Impact factor: 1.366

3.  Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.

Authors:  R E Dupuis; S N Lichtman; G M Pollack
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

4.  The outcome from severe head injury with early diagnosis and intensive management.

Authors:  D P Becker; J D Miller; J D Ward; R P Greenberg; H F Young; R Sakalas
Journal:  J Neurosurg       Date:  1977-10       Impact factor: 5.115

Review 5.  A comparison of the Glasgow Coma Scale and the Reaction Level Scale (RLS85).

Authors:  J E Starmark; D Stålhammar; E Holmgren; B Rosander
Journal:  J Neurosurg       Date:  1988-11       Impact factor: 5.115

Review 6.  Valproate-induced hyperammonemic encephalopathy.

Authors:  Alberto Verrotti; Daniela Trotta; Guido Morgese; Francesco Chiarelli
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

7.  The efficacy of barbiturate coma in the management of uncontrolled intracranial hypertension following neurosurgical trauma.

Authors:  M W Lee; S A Deppe; M E Sipperly; R R Barrette; D R Thompson
Journal:  J Neurotrauma       Date:  1994-06       Impact factor: 5.269

8.  Outcome after traumatic brain injury improved by an organized secondary insult program and standardized neurointensive care.

Authors:  Kristin Elf; Pelle Nilsson; Per Enblad
Journal:  Crit Care Med       Date:  2002-09       Impact factor: 7.598

9.  Effect of L-carnitine supplementation on acute valproate intoxication.

Authors:  K Murakami; T Sugimoto; M Woo; N Nishida; H Muro
Journal:  Epilepsia       Date:  1996-07       Impact factor: 5.864

10.  [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase].

Authors:  P Bourrier; N Varache; P Alquier; D Rabier; P Kamoun; G Lorre; G Alhayek
Journal:  Presse Med       Date:  1988-11-05       Impact factor: 1.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.